KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Amortizatization of Intangibles (2016 - 2025)

Historic Amortizatization of Intangibles for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Q3 2025 value amounting to $978000.0.

  • Biomarin Pharmaceutical's Amortizatization of Intangibles fell 4961.36% to $978000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.4 million, marking a year-over-year decrease of 4020.52%. This contributed to the annual value of $8.3 million for FY2024, which is 956.87% down from last year.
  • Biomarin Pharmaceutical's Amortizatization of Intangibles amounted to $978000.0 in Q3 2025, which was down 4961.36% from $1.4 million recorded in Q2 2025.
  • Biomarin Pharmaceutical's Amortizatization of Intangibles' 5-year high stood at $2.6 million during Q2 2023, with a 5-year trough of -$1.9 million in Q4 2021.
  • Over the past 5 years, Biomarin Pharmaceutical's median Amortizatization of Intangibles value was $1.4 million (recorded in 2025), while the average stood at $687894.7.
  • As far as peak fluctuations go, Biomarin Pharmaceutical's Amortizatization of Intangibles crashed by 557727.27% in 2021, and later soared by 43502.24% in 2023.
  • Over the past 5 years, Biomarin Pharmaceutical's Amortizatization of Intangibles (Quarter) stood at -$1.9 million in 2021, then soared by 137.21% to $698000.0 in 2022, then soared by 250.57% to $2.4 million in 2023, then decreased by 29.46% to $1.7 million in 2024, then crashed by 43.34% to $978000.0 in 2025.
  • Its last three reported values are $978000.0 in Q3 2025, $1.4 million for Q2 2025, and $1.4 million during Q1 2025.